Overview
The Chemours Company, based in the United States, operates primarily in the chemicals industry. Founded as a spin-off from DuPont in 2015, Chemours specializes in the production of high-performance chemicals used in various sectors including refrigeration, electronics, and industrial processes. Among its leading products are prominent brands like Teflon and Ti-Pure. The company is also actively involved in sustainability projects; for instance, its Opteon range of refrigerants is designed to reduce environmental impact with low global warming potential. This initiative aligns with its broader commitment to Responsible Care®, emphasizing safety and environmental stewardship across its global operations. As such, Chemours represents a key player in the innovative and sustainability-driven chemical sector.
AI+ Ask Fintel’s AI assistant about The Chemours Company.
Thinking about good questions…
Basic Stats
The share price of The Chemours Company as of September 5, 2025 is $15.66 / share. This is an increase of 1.69% from the prior week. The market cap (or net worth) of The Chemours Company as of September 5, 2025 is $2,344.28 MM.
The Factor Analysis chart (below right) shows a view of The Chemours Company from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 2,344.28 MM |
| EV | 5,948.28 MM |
| Shares Out. | 149.70 MM |
| Earnings Date | |
| EPS (TTM) | -2.75 |
| Dividend Yield | 2.23 % |
| Ex-Dividend Date | 2025-08-15 |
| Borrow Rate | 0.36 |
| Short Shares Avail. | 1.90 MM |
| Short Interest | 18.18 MM |
| Short Float | 12.85 % |
| Days to Cover | 6.82 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -15.35 % |
| Volatility (1 yr) | 0.64 |
| Beta | 1.51 |
| Sharpe Ratio (1 yr) | -0.31 |
| Sortino Ratio (1 yr) | -0.59 |
| PE Ratio | -5.69 |
| Price/Book | 9.81 |
| Price/TBV | 12.40 |
| Book/Market | 0.10 |
| EBIT/EV | -0.05 |
| EBIT(3yr avg)/EV | -0.01 |
| ROA | -0.06 |
| ROE | -0.57 |
| ROIC | -0.09 |
| CROIC | -0.01 |
| OCROIC | 0.06 |
| Implied Volatility | 55.61 % |
| Put/Call OI Ratio | 0.56 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for The Chemours Company is $15.43. The forecasts range from a low of $11.11 to a high of $18.90. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for The Chemours Company. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-10 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2022-12-15 | Citigroup | Neutral | Maintains | |
| 2022-11-01 | Credit Suisse | Underperform | Initiate | |
| 2022-10-27 | BMO Capital | Outperform | Maintains | |
| 2022-10-25 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-10-13 | Goldman Sachs | Neutral | Initiate | |
| 2022-10-05 | Argus Research | Buy | Hold | Downgrade |
| 2022-09-27 | Barclays | Equal-Weight | Maintains | |
| 2022-09-23 | BMO Capital | Outperform | Maintains | |
| 2022-09-22 | RBC Capital | Outperform | Maintains | |
| 2022-08-01 | RBC Capital | Outperform | Maintains | |
| 2022-07-29 | UBS | Neutral | Maintains | |
| 2022-06-14 | B of A Securities | Buy | Neutral | Downgrade |
| 2022-05-09 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-05-09 | Barclays | Equal-Weight | Maintains | |
| 2022-05-04 | RBC Capital | Outperform | Maintains | |
| 2022-02-15 | RBC Capital | Outperform | Maintains | |
| 2022-02-14 | JP Morgan | Neutral | Maintains | |
| 2022-01-04 | UBS | Neutral | Maintains | |
| 2021-11-08 | RBC Capital | Outperform | Maintains | |
| 2021-08-03 | RBC Capital | Outperform | Maintains | |
| 2021-06-10 | Wolfe Research | Outperform | Initiate | |
| 2021-06-09 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2021-05-20 | B of A Securities | Buy | Initiate | |
| 2021-05-10 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-05-06 | Argus Research | Hold | Buy | Upgrade |
| 2021-02-16 | Morgan Stanley | Equal-Weight | Maintains | |
| 2021-01-08 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2020-12-14 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-12-04 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2020-11-16 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-11-05 | BMO Capital | Outperform | Maintains | |
| 2020-08-04 | Citigroup | Neutral | Maintains | |
| 2020-08-03 | RBC Capital | Sector Perform | Maintains | |
| 2020-07-09 | UBS | Neutral | Maintains | |
| 2020-05-08 | UBS | Neutral | Maintains | |
| 2020-05-07 | SunTrust Robinson Humphrey | Hold | Maintains | |
| 2020-04-09 | Citigroup | Neutral | Maintains | |
| 2020-04-03 | CFRA | Strong Buy | Hold | Downgrade |
| 2020-04-01 | RBC Capital | Sector Perform | Maintains | |
| 2020-03-30 | Morgan Stanley | Equal-Weight | Maintains | |
| 2020-03-26 | BMO Capital | Outperform | Maintains | |
| 2020-02-18 | SunTrust Robinson Humphrey | Hold | Maintains | |
| 2019-12-20 | JP Morgan | Neutral | Maintains | |
| 2019-11-07 | BMO Capital | Outperform | Maintains | |
| 2019-11-06 | Citigroup | Neutral | Maintains | |
| 2019-10-02 | UBS | Neutral | Maintains | |
| 2019-09-09 | BMO Capital | Outperform | Maintains | |
| 2019-08-20 | Susquehanna | Neutral | Positive | Upgrade |
| 2019-08-09 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2019-08-06 | Argus | Buy | Hold | Downgrade |
| 2019-08-05 | BMO Capital | Outperform | Maintains | |
| 2019-05-06 | JP Morgan | Overweight | Neutral | Downgrade |
| 2019-04-15 | SunTrust Robinson Humphrey | Hold | Buy | Upgrade |
| 2019-02-19 | Susquehanna | Positive | Neutral | Downgrade |
| 2018-11-05 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-11-02 | Citigroup | Buy | Neutral | Downgrade |
| 2018-10-11 | Citigroup | Buy | Buy | Maintains |
| 2018-09-25 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-08-06 | BMO Capital | Outperform | Outperform | Maintains |
| 2018-07-31 | SunTrust Robinson Humphrey | Hold | Initiate | |
| 2018-07-18 | RBC Capital | Outperform | Initiate | |
| 2018-07-17 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-07-11 | Citigroup | Buy | Buy | Maintains |
| 2018-05-21 | Vertical Research | Buy | Initiate | |
| 2018-05-08 | Citigroup | Buy | Buy | Maintains |
| 2018-04-10 | Citigroup | Buy | Buy | Maintains |
| 2018-03-28 | BMO Capital | Outperform | Initiate | |
| 2018-01-30 | Morgan Stanley | Equal-Weight | Initiate | |
| 2017-12-06 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2017-11-06 | Barclays | Overweight | Maintains | |
| 2017-11-03 | UBS | Neutral | Maintains | |
| 2017-08-07 | UBS | Sell | Neutral | Upgrade |
| 2017-07-05 | Citigroup | Neutral | Buy | Upgrade |
| 2017-05-12 | JP Morgan | Neutral | Overweight | Upgrade |
| 2017-03-29 | Jefferies | Hold | Buy | Upgrade |
| 2017-02-17 | Susquehanna | Neutral | Positive | Upgrade |
| 2016-12-12 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2016-09-01 | Jefferies | Hold | Maintains | |
| 2016-08-11 | Citigroup | Neutral | Maintains | |
| 2016-08-10 | Argus | Hold | Buy | Upgrade |
| 2016-08-09 | UBS | Sell | Maintains | |
| 2016-07-15 | Citigroup | Neutral | Maintains | |
| 2016-04-18 | Citigroup | Neutral | Maintains | |
| 2016-03-14 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2016-02-16 | Jefferies | Buy | Hold | Downgrade |
| 2015-12-18 | Barclays | Overweight | Maintains | |
| 2015-09-18 | Argus | Hold | Initiate | |
| 2015-08-07 | JP Morgan | Underweight | Upgrade | |
| 2015-07-28 | Susquehanna | Neutral | Initiate | |
| 2015-07-27 | Susquehanna | Neutral | Initiate | |
| 2015-07-15 | Goldman Sachs | Neutral | Initiate | |
| 2015-07-06 | UBS | Neutral | Initiate | |
| 2015-07-06 | Barclays | Overweight | Initiate | |
| 2012-07-30 | Goldman Sachs | Buy | Maintains | |
| 2023-01-11 | UBS | Neutral | Maintains | |
| 2023-01-11 | B of A Securities | Neutral | Buy | Upgrade |
| 2023-01-24 | UBS | Neutral | Buy | Upgrade |
| 2023-02-13 | RBC Capital | Sector Perform | Maintains | |
| 2023-02-13 | Citigroup | Neutral | Maintains | |
| 2023-02-10 | Credit Suisse | Underperform | Maintains | |
| 2023-02-14 | Goldman Sachs | Neutral | Maintains | |
| 2023-04-28 | Credit Suisse | Underperform | Maintains | |
| 2023-05-01 | BMO Capital | Outperform | Maintains | |
| 2023-05-01 | RBC Capital | Sector Perform | Maintains | |
| 2023-05-31 | JP Morgan | Neutral | Neutral | Maintains |
| 2023-06-05 | BMO Capital | Outperform | Outperform | Maintains |
| 2023-06-09 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-06-13 | UBS | Buy | Maintains | |
| 2023-10-04 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-07-19 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2024-03-05 | UBS | Buy | Neutral | Downgrade |
| 2023-10-30 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-06-22 | B of A Securities | Buy | Neutral | Downgrade |
| 2023-10-31 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2023-12-01 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2023-11-07 | JP Morgan | Neutral | Neutral | Maintains |
| 2024-02-29 | BMO Capital | Outperform | Underperform | Downgrade |
| 2023-08-02 | BMO Capital | Outperform | Outperform | Maintains |
| 2023-07-31 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2023-07-11 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-01 | Morgan Stanley | Equal-Weight | Equal-Weight | Reiterate |
| 2023-10-30 | BMO Capital | Outperform | Outperform | Maintains |
| 2023-10-30 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-10-30 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-04-09 | BMO Capital | Market Perform | Outperform | Upgrade |
| 2024-04-02 | UBS | Neutral | Neutral | Maintains |
| 2024-04-02 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-03-01 | BMO Capital | Outperform | Underperform | Downgrade |
| 2024-06-07 | Mizuho | Neutral | Initiate | |
| 2024-07-09 | UBS | Neutral | Buy | Upgrade |
| 2024-10-11 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-11-05 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-11-05 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-03-27 | Mizuho | Neutral | Outperform | Upgrade |
| 2024-12-12 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-08-06 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-08-06 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-01-28 | Truist Securities | Buy | Initiate | |
| 2024-09-25 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-09-03 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-10-07 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-02-24 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2024-11-06 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-06 | UBS | Buy | Buy | Maintains |
| 2024-08-06 | JP Morgan | Neutral | Neutral | Maintains |
| 2025-05-07 | UBS | Buy | Buy | Maintains |
| 2025-01-13 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-01-07 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-01-07 | Mizuho | Neutral | Neutral | Maintains |
| 2025-02-19 | BMO Capital | Outperform | Outperform | Maintains |
| 2025-04-01 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-14 | Truist Securities | Buy | Buy | Maintains |
| 2025-05-14 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2025-05-12 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-07-03 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-05-28 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-05-08 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-07-15 | Mizuho | Outperform | Outperform | Maintains |
